Viral Vector & Plasmid DNA Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Viral Vectors, Non-viral Vectors); Application (Cancer, Inherited Disorders, Viral Infections, Others), and Geography
Publication Month: Jun 2020 | Report Code: TIPRE00003074 | No. of Pages: 140 | Category: Biotechnology | Status: Published
The viral vector & plasmid DNA manufacturing market is expected to reach US$ 2,247.7 million by2027 from US$ 459.4million in 2019. The market is estimated to grow with a CAGR of 22.1% from 2020 to 2027.
Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are naked DNA, particle-based, and chemical-based. Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders, and infectious diseases across the world are expected to upsurge the market growth. Additionally,growth in the global healthcare market is likely to have a positive impact on the Viral Vector & Plasmid DNA Manufacturing market in the coming years.
Lucrative Regional Viral Vector & Plasmid DNA Manufacturing Market
Get more information on this report :
Market Insights
Increasing Prevalence of Genetic Disorders and Infectious Diseases
According to a study published by National Hemophilia Foundation in 2015, an estimated 400,000 people across the globe are suffering from hemophilia. Further, according to a study published by the NIH in 2019, sickle cell anemia affects an estimated 100,000 people in the US. The application of gene therapy for the treatment of viral infections such as herpes simplex viruses, adeno-associated viruses, poxviruses, and retroviruses is expected to drive the adoption of gene therapies as one of the prominent treatment alternatives, which will eventually boost the growth of the viral vectors and plasmid DNA manufacturing market during the forecast period.
Gene therapies with the help of viral vectors are widely recommended for a range of monogenic disorders, such as sickle cell anemia, severe combined immunodeficiency, cystic fibrosis, hemophilia, Duchenne muscular dystrophy, Parkinson’s disease, and Gaucher disease. For instance, in October 2019, a group of researchers at the National Institutes of Health (NIH) developed a new improved viral vector for the treatment of sickle cell anemia. According to the researchers, the new vector is 10 times efficient than already existing viral vectors in the market.
Product Insights
Based on product, the viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the larger share of the market in 2019, owing to the factor that these are used in basic research, gene therapy, and vaccine preparation. Moreover, they can be of different types such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and hybrids. Additionally, effective gene delivery, high transfection efficiency, and stable gene expression have made viral vectors a preferred choice for gene transfer. Hence the growing demand is likely to propel the growth of the market at a highest CAGR during the forecast period.
Global Viral Vector & Plasmid DNA Manufacturing Market, by Product– 2019 & 2027
Get more information on this report :
End User Insights
Based on end user, the viral vector & plasmid DNA manufacturing market is segmented into cancer, inherited disorders, viral infections, and others. The cancer segment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period. The growing prevalence of cancer is likely to grow market at a faster CAGR.
Strategic Insights
Product launch and expansion are commonly adopted by companies to expand their footprint and product portfolio worldwide in order to meet the growing demand. The market players operating in the viral vector & plasmid DNA manufacturing market adopt the strategy of collaboration and partnership to enlarge customer base across the world, which also permits the players to maintain their brand name in the global market.
By Product
- Viral Vectors
- Non-Viral Vectors
By Application
- Cancer
- Inherited Disorders
- Viral Infections
- Others
By Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of Asia Pacific
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
South and Central America (SCAM)
- Brazil
- Argentina
- Rest of South America
Company Profiles
- Brammer Bio
- Sanofi
- FUJIFILM Diosynth Biotechnologies
- Cell and Gene Therapy Catapult
- Cobra Biologics
- FinVector
- Kaneka Eurogentec S.A.
- MassBiologics
- Spark Therapeutics
- Uniqure
Frequently Asked Questions
The List of Companies - Portable and Wearable Dialysis Devices Market
- Brammer Bio
- Sanofi
- FUJIFILM Diosynth Biotechnologies
- Cell and Gene Therapy Catapult
- Cobra Biologics
- FinVector
- Kaneka Eurogentec S.A.
- MassBiologics
- Spark Therapeutics
- Uniqure
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the viral vector and plasmid DNA manufacturing market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global viral vector and plasmid DNA manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Get the Latest COVID-19 Analysis on this market
Have a Question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
-
$3000
-
$4550 $3640
-
$6550 $5240
-
$8550 $6840
-
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.
Inquire for Discount